SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-151833
Filing Date
2023-05-23
Accepted
2023-05-23 16:25:53
Documents
7
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A d487231ddef14a.htm DEF 14A 598181
2 GRAPHIC g487231dsp009.jpg GRAPHIC 144726
3 GRAPHIC g487231dsp010.jpg GRAPHIC 124471
4 GRAPHIC g487231g11i11.jpg GRAPHIC 54741
5 GRAPHIC g487231g22s22.jpg GRAPHIC 28859
6 GRAPHIC g487231g49a10.jpg GRAPHIC 77511
7 GRAPHIC g487231g50s50.jpg GRAPHIC 74324
  Complete submission text file 0001193125-23-151833.txt   1272160
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36332 | Film No.: 23949219
SIC: 2834 Pharmaceutical Preparations